Poly Medicure Limited (BOM:531768)
India · Delayed Price · Currency is INR 1,288.95
-28.95 (-2.20%)
At close: Feb 13, 2026
Poly Medicure Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 17,816 | 16,698 | 13,758 | 11,152 | 9,231 | 7,865 | |
Revenue Growth (YoY) | 10.86% | 21.37% | 23.36% | 20.82% | 17.37% | 14.44% |
Cost of Revenue | 5,702 | 5,588 | 4,867 | 4,090 | 3,506 | 2,636 |
Gross Profit | 12,114 | 11,110 | 8,891 | 7,062 | 5,724 | 5,229 |
Selling, General & Admin | 3,671 | 3,106 | 2,516 | 2,076 | 1,671 | 1,448 |
Research & Development | 270.62 | 245.71 | 194.42 | 178.03 | 187.71 | 131.45 |
Other Operating Expenses | 3,651 | 3,219 | 2,584 | 2,109 | 1,730 | 1,506 |
Operating Expenses | 8,569 | 7,394 | 5,928 | 4,934 | 4,128 | 3,560 |
Operating Income | 3,545 | 3,716 | 2,963 | 2,128 | 1,596 | 1,669 |
Interest Expense | -137.46 | -116.93 | -109.34 | -62.27 | -38.28 | -69.84 |
Interest & Investment Income | 117.83 | 117.83 | 118.36 | 153.29 | 94.75 | 43.03 |
Earnings From Equity Investments | 62.5 | 51.8 | 25.27 | 19.27 | 24.47 | 33.11 |
Currency Exchange Gain (Loss) | 213.27 | 213.27 | 152.83 | 113.82 | 118.84 | 67.27 |
Other Non Operating Income (Expenses) | 458.78 | 83.7 | 62.4 | 62.26 | 55.11 | 23.2 |
EBT Excluding Unusual Items | 4,260 | 4,066 | 3,212 | 2,414 | 1,851 | 1,765 |
Gain (Loss) on Sale of Investments | 439.96 | 439.96 | 209.49 | -40.07 | 96 | 35.14 |
Gain (Loss) on Sale of Assets | 1.2 | 1.2 | 6.23 | 1 | 5.31 | 0.07 |
Other Unusual Items | -50 | 18.04 | 14.53 | - | - | - |
Pretax Income | 4,651 | 4,525 | 3,443 | 2,375 | 1,952 | 1,801 |
Income Tax Expense | 1,176 | 1,140 | 860.09 | 582.09 | 487.39 | 441.8 |
Net Income | 3,477 | 3,386 | 2,583 | 1,793 | 1,465 | 1,359 |
Net Income to Common | 3,477 | 3,386 | 2,583 | 1,793 | 1,465 | 1,359 |
Net Income Growth | 10.35% | 31.09% | 44.05% | 22.37% | 7.83% | 41.72% |
Shares Outstanding (Basic) | 102 | 99 | 96 | 96 | 96 | 89 |
Shares Outstanding (Diluted) | 102 | 99 | 96 | 96 | 96 | 89 |
Shares Change (YoY) | 4.61% | 3.36% | - | 0.06% | 7.64% | 0.99% |
EPS (Basic) | 34.15 | 34.13 | 26.92 | 18.69 | 15.28 | 15.25 |
EPS (Diluted) | 34.12 | 34.11 | 26.90 | 18.67 | 15.27 | 15.24 |
EPS Growth | 5.46% | 26.80% | 44.08% | 22.27% | 0.20% | 40.33% |
Free Cash Flow | - | -906.06 | -109.34 | -482.23 | -321.06 | 236.01 |
Free Cash Flow Per Share | - | -9.13 | -1.14 | -5.02 | -3.35 | 2.65 |
Dividend Per Share | - | 3.500 | 3.000 | 3.000 | 2.500 | 2.500 |
Dividend Growth | - | 16.67% | - | 20.00% | - | 25.00% |
Gross Margin | 68.00% | 66.53% | 64.63% | 63.32% | 62.02% | 66.49% |
Operating Margin | 19.90% | 22.25% | 21.54% | 19.08% | 17.29% | 21.22% |
Profit Margin | 19.52% | 20.28% | 18.77% | 16.08% | 15.87% | 17.28% |
Free Cash Flow Margin | - | -5.43% | -0.80% | -4.32% | -3.48% | 3.00% |
EBITDA | 4,493 | 4,521 | 3,577 | 2,677 | 2,118 | 2,125 |
EBITDA Margin | 25.22% | 27.08% | 26.00% | 24.01% | 22.94% | 27.02% |
D&A For EBITDA | 948.36 | 805.07 | 614.02 | 549.8 | 521.67 | 456.63 |
EBIT | 3,545 | 3,716 | 2,963 | 2,128 | 1,596 | 1,669 |
EBIT Margin | 19.90% | 22.25% | 21.54% | 19.08% | 17.29% | 21.22% |
Effective Tax Rate | 25.28% | 25.18% | 24.98% | 24.51% | 24.96% | 24.54% |
Revenue as Reported | 19,082 | 17,590 | 14,345 | 11,514 | 9,610 | 8,049 |
Advertising Expenses | - | 60.5 | 33.91 | 28.51 | 12.89 | 8.02 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.